Veru Inc. VERU
2.14 USD +0.02 (+0.94%)
At closeNov 11, 2026, 4:00 PM EST
2.11 -0.03 -1.59%
After hours · Nov 11, 4:00 PM ET
2.07 Day range 2.17
2.04 52-week range 7.33
- YTD
- 0.00%
- 1 year
- -18.32%
News
benzinga.com Veru To Present Phase 2b QUALITY Study Analysis Of Physical Function In Older Obesity Patients At ObesityWeek 2026 Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of metabolic diseases and oncology, today announced Veru’s Chief…
globenewswire.com Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026 MIAMI, FL, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of metabolic…
benzinga.com WestPark Capital Initiates Coverage On Veru with Buy Rating, Announces Price Target of $28 WestPark Capital analyst Ed Arce initiates coverage on Veru (NASDAQ:VERU) with a Buy rating and announces Price Target of $28.
benzinga.com Veru Q3 EPS $(0.30) Beats $(0.32) Estimate Veru (NASDAQ:VERU) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 40 percent increase over losses of $(0.50) per share…
benzinga.com Veru Completes Patient Enrollment In Phase 2b PLATEAU Clinical Trial To Evaluate Effect Of Oral Enobosarm 3 Mg Versus To Treat Obesity Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com Veru Strikes Clinical Supply Agreement With Novo Nordisk To Mull Combination Of Enobosarm With Wegovy https://www.sec.gov/ix?doc=/Archives/edgar/data/863894/000143774926019478/veru20260601_8k.htm
benzinga.com Oppenheimer Maintains Outperform on Veru, Lowers Price Target to $24 Oppenheimer analyst Leland Gershell maintains Veru (NASDAQ:VERU) with a Outperform and lowers the price target from $25 to $24.
benzinga.com Transcript: Veru Q2 2026 Earnings Conference Call 
benzinga.com Earnings Scheduled For May 13, 2026 - benzinga.com Veru Q2 EPS $(0.12) Beats $(0.28) Estimate Veru (NASDAQ:VERU) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.28) by 57.14 percent. This is a 76 percent increase over losses of $(0.50) per share…
benzinga.com Veru Files Prospectus For Offering $200M Mixed Shelf https://www.sec.gov/Archives/edgar/data/863894/000119312526145576/d84893ds3.htm
benzinga.com Veru Enrolls First Patient In Phase 2b PLATEAU Clinical Trial Of Enobosarm, Oral SARM, To Preserve Muscle And Physical Function And To Augment Fat And Weight Loss When Combined With Wegovy -- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older…- benzinga.com Veru Q1 EPS $(0.26) Beats $(0.47) Estimate Veru (NASDAQ:VERU) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.47) by 44.68 percent. This is a 57.38 percent increase over losses of $(0.61) per…
- benzinga.com Earnings Scheduled For February 11, 2026
benzinga.com A Look at Veru's Upcoming Earnings Report 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com Canaccord Genuity Initiates Coverage On Veru with Buy Rating, Announces Price Target of $25 Canaccord Genuity analyst Edward Nash initiates coverage on Veru (NASDAQ:VERU) with a Buy rating and announces Price Target of $25.
- benzinga.com Earnings Scheduled For December 17, 2025
benzinga.com A Look Ahead: Veru's Earnings Forecast 
benzinga.com Top Wall Street Forecasters Revamp Veru Expectations Ahead Of Q4 Earnings 
benzinga.com Top Stocks With Earnings This Week: Micron, FuelCell, Carnival and More Investors are prepping for this week's earnings reports which include homebuilders, several apparel companies and a big tech company.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Earnings Scheduled For August 12, 2025 - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Earnings Scheduled For May 8, 2025
benzinga.com Earnings Scheduled For February 13, 2025 - benzinga.com 12 Consumer Staples Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Consumer Staples Stocks Moving In Thursday's After-Market Session
- benzinga.com Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
benzinga.com Comstock And 2 Other Stocks Under $2 Insiders Are Buying - benzinga.com Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic…
- benzinga.com Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.
- benzinga.com Earnings Scheduled For February 8, 2024 Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million.
- benzinga.com Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at…
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 311 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 112 companies set new 52-week lows.
- benzinga.com 11 Consumer Staples Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's session, 275 companies made new 52-week lows.
- benzinga.com Earnings Scheduled For August 10, 2023 Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
- benzinga.com Earnings Scheduled For May 11, 2023 Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its…
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 220 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 76 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 93 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 469 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 175 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's session, 104 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 198 companies hit new 52-week lows.